Case 23-2006: A 36-year-old man with numbness in the right hand and hypertension

New England Journal of Medicine

Volumn 355, Issue 4, 2006, Pages 394-402

  Iliopoulos, Othon ^a,b   Chan Smutko, Gayun ^a   Gonzalez, R Gilberto ^a,b   Louis, David N ^a,b   Stone, James R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ATENOLOL; HYDROCORTISONE; NORTRIPTYLINE; PHENOXYBENZAMINE; TERAZOSIN;

ADRENAL CORTEX TUMOR; ADRENALECTOMY; ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAPHY; HAND PARESTHESIA; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; MALE; MEDICAL ASSESSMENT; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; FATALITY; GENETICS; HAND; HYPESTHESIA; MUTATION; PATHOLOGY; PEDIGREE;

ADRENAL GLAND NEOPLASMS; ADULT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HAND; HIPPEL-LINDAU DISEASE; HUMANS; HYPERTENSION; HYPESTHESIA; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; PARAGANGLIOMA; PEDIGREE; PHEOCHROMOCYTOMA;

EID: 33746454770     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc069014     Document Type: Article

References (29)

1. Kudva YC, Sawka AM, Young WF Jr. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003;88:4533-9.
2. Eisenhofer G, Lenders JWM, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999;340:1872-9.
3. Neumann HP, Hoegerle S, Manz T, Brenner K, Iliopoulos O. How many pathways to pheochromocytoma? Semin Nephrol 2002;22:89-99.
4. Schuffenecker I, Ginet N, Goldgar D, et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Am J Hum Genet 1997;60:233-7.
5. Lazaro C, Ravella A, Gaona A, Volpini V, Estivill X. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994;331:1403-7.
6. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 2002;39:178-83.
7. Sgambati MT, Stolle C, Choyke PL, et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000;66:84-91.
8. Neumann HPH, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
9. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
10. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.
11. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202.
12. Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. Lancet 2003; 361:2059-67.
13. Maher ER, Kaelin WG Jr. Von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-91.
14. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. Von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995;194:629-42. [Erratum, Radiology 1995;196:582.]
15. Wittebol-Post D, Hes FJ, Lips CJM. The eye in Von Hippel-Lindau disease: long term follow up of screening and treatment recommendations. J Intern Med 1998;243:555-61.
16. Latif F, Tory K, Gnarra J, et al. Identification of the Von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
17. Iliopoulos O. VHL disease: genetic and clinical observations. In: Dahia PML, Eng C, eds. Genetic disorders of endocrine neoplasia. Vol. 28. Basel, Switzerland: Karger, 2001:131-66.
18. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-6295S.
19. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
20. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
21. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004;2:89-95.
22. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1(3):E83.
23. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
24. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-57.
25. Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998;58:504-8.
26. Vortmeyer AO, Frank S, Jeong SY, et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003;63:7051-5.
27. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-64.
28. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997;40:1016-26.
29. van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med 1966;274:1102-8.